Q4: 2026-02-04 Earnings Summary
EPS of $0.80 beats by $0.02
| Revenue of $5.29B (15.90% Y/Y) beats by $4.95M
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call February 4, 2026 8:00 AM EST
Company Participants
Lauren Tengler – Director of Investor Relations
Michael Mahoney – Chairman, President & CEO
Jonathan Monson – Executive VP & CFO
Ken Stein – Senior VP & Global Chief Medical Officer
Conference Call Participants
Robert Marcus – JPMorgan Chase & Co, Research Division
Larry Biegelsen – Wells Fargo Securities, LLC, Research Division
Travis Steed – BofA Securities, Research Division
Frederick Wise – Stifel, Nicolaus & Company, Incorporated, Research Division
Joanne Wuensch – Citigroup Inc., Research Division
David Roman – Goldman Sachs Group, Inc., Research Division
Patrick Wood – Morgan Stanley, Research Division
Danielle Antalffy – UBS Investment Bank, Research Division
Michael Polark – Wolfe Research, LLC
Matthew Taylor – Jefferies LLC, Research Division
Joshua Jennings – TD Cowen, Research Division
Christopher Pasquale – Nephron Research LLC
Presentation
Operator
Good morning, and welcome to the Boston Scientific Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Lauren Tengler
Director of Investor Relations
Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by our Chief Medical Officer, Dr. Ken Stein.
We issued a press release earlier this morning announcing our Q4 and full year 2025 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as reconciliations of the non-GAAP measures used in today’s call can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for
